{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:09:40Z","timestamp":1785380980088,"version":"3.55.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00256-025-04884-8","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:52:46Z","timestamp":1738831966000},"page":"2275-2289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Imaging in clinical trials for psoriatic arthritis: a scoping review"],"prefix":"10.1007","volume":"54","author":[{"given":"Andrew","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainge","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Dennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Yacyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-4940","authenticated-orcid":false,"given":"Matthew D.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"10","key":"4884_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"6","key":"4884_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4884_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001223","volume":"6","author":"G Haugeberg","year":"2020","unstructured":"Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6(1): e001223.","journal-title":"RMD Open"},{"issue":"1","key":"4884_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Method. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Method"},{"issue":"2","key":"4884_CR5","first-page":"130","volume":"94","author":"JM Glanville","year":"2006","unstructured":"Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc. 2006;94(2):130\u20136.","journal-title":"J Med Libr Assoc"},{"issue":"8","key":"4884_CR6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4884_CR7","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Alan JK, Francis XB, Evan LS, Stanley BC, Peter O, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264\u201372.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4884_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279\u201389.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4884_CR9","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/art.22805","volume":"56","author":"D van der Heijde","year":"2007","unstructured":"van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56(8):2698\u2013707.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4884_CR10","first-page":"869","volume":"35","author":"CE Antoni","year":"2008","unstructured":"Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35(5):869\u201376.","journal-title":"J Rheumatol"},{"issue":"8","key":"4884_CR11","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504\u201317.","journal-title":"Arthritis Rheum"},{"issue":"10012","key":"4884_CR12","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised, controlled trial. Lancet. 2015;386(10012):2489\u201398.","journal-title":"Lancet"},{"key":"4884_CR13","doi-asserted-by":"crossref","unstructured":"Mease Philip J, McInnes Iain B, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373(14):1329\u20131339","DOI":"10.1056\/NEJMoa1412679"},{"key":"4884_CR14","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res 2016;68(10):N.PAG-N.PAG"},{"issue":"11","key":"4884_CR15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis. Arthritis Rheum. 2017;69(11):2151\u201361.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4884_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4884_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"4884_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350.","journal-title":"N Engl J Med"},{"issue":"6","key":"4884_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landewe R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4884_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3899\/jrheum.180681","volume":"46","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, et al. Radiographic progression inhibition with intravenous golimumab in psoriatic arthritis: week 24 results of a phase III, randomized, double-blind, placebo-controlled trial. J Rheumatol. 2019;46(6):595\u2013602.","journal-title":"J Rheumatol"},{"issue":"10230","key":"4884_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. 2020;395(10230):1126\u201336.","journal-title":"The Lancet"},{"issue":"2","key":"4884_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"4884_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, Landewe R, Merola JF, Ritchlin CT, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet (London, England). 2023;401(10370):25\u201337.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"4884_CR24","first-page":"712","volume":"33","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712\u201321.","journal-title":"J Rheumatol"},{"issue":"3","key":"4884_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaad.2008.09.050","volume":"60","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60(3):402\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"4884_CR26","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.22645","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67(12):1739\u201349.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"4884_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000582","volume":"4","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018;4(1): e000582.","journal-title":"RMD Open"},{"issue":"10","key":"4884_CR28","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","volume":"59","author":"V Chandran","year":"2020","unstructured":"Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, et al. Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4884_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/acr.23905","volume":"72","author":"ME Husni","year":"2020","unstructured":"Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, et al. Efficacy and safety of intravenous golimumab through one year in patients with active psoriatic arthritis. Arthritis Care Res. 2020;72(6):806\u201313.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"4884_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/09546630601028703","volume":"17","author":"C De Felice","year":"2006","unstructured":"De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients\u2019 quality of life. J Dermatolog Treat. 2006;17(6):355\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"4884_CR31","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1002\/art.21376","volume":"52","author":"ZN Jahangier","year":"2005","unstructured":"Jahangier ZN, Jacobs JW, Lafeber FP, Moolenburgh JD, Swen WA, Bruyn GA, et al. Is radiation synovectomy for arthritis of the knee more effective than intraarticular treatment with glucocorticoids? Results of an eighteen-month, randomized, double-blind, placebo-controlled, crossover trial. Arthritis Rheum. 2005;52(11):3391\u2013402.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4884_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis & rheumatology (Hoboken, NJ). 2019;71(7):1112\u201324.","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"4","key":"4884_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/03009742.2019.1571222","volume":"48","author":"T Weitoft","year":"2019","unstructured":"Weitoft T, \u00d6berg K. Dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis: a randomized controlled study. Scand J Rheumatol. 2019;48(4):279\u201383.","journal-title":"Scand J Rheumatol"},{"issue":"13","key":"4884_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"B McInnes Iain","year":"2021","unstructured":"McInnes Iain B, Anderson Jaclyn K, Magrey M, Merola Joseph F, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"4884_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939\u201348.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4884_CR36","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/ard.2010.142539","volume":"70","author":"F McQueen","year":"2011","unstructured":"McQueen F, Lloyd R, Doyle A, Robinson E, Lobo M, Exeter M, et al. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. Ann Rheum Dis. 2011;70(6):1091\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4884_CR37","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3899\/jrheum.141010","volume":"42","author":"D Glinatsi","year":"2015","unstructured":"Glinatsi D, Bird P, Gandjbakhch F, Mease PJ, Boyesen P, Peterfy CG, et al. Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial. J Rheumatol. 2015;42(12):2473\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"4884_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13075-017-1364-3","volume":"19","author":"A Szentpetery","year":"2017","unstructured":"Szentpetery A, Heffernan E, Gogarty M, Mellerick L, McCormack J, Haroon M, et al. Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis. Arthritis Res Ther. 2017;19(1):158.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"4884_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations:results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4884_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.10671","volume":"47","author":"C Antoni","year":"2002","unstructured":"Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002;47(5):506\u201312.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4884_CR41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/ard.2006.063818","volume":"66","author":"H Marzo-Ortega","year":"2007","unstructured":"Marzo-Ortega H, McGonagle D, Rhodes LA, Tan AL, Conaghan PG, O\u2019Connor P, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis. 2007;66(6):778\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4884_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13075-018-1565-4","volume":"20","author":"M Haroon","year":"2018","unstructured":"Haroon M, Ahmad M, Baig MN, Mason O, Rice J, FitzGerald O. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Res Ther. 2018;20(1):73.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"4884_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","volume":"79","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020;79(4):490\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4884_CR44","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/ar3228","volume":"13","author":"EK Pontifex","year":"2011","unstructured":"Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy\u2013a single centre, open-label study. Arthritis Res Ther. 2011;13(1):R7.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"4884_CR45","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/rheumatology\/kei094","volume":"44","author":"LA Rhodes","year":"2005","unstructured":"Rhodes LA, Grainger AJ, Keenan AM, Thomas C, Emery P, Conaghan PG. The validation of simple scoring methods for evaluating compartment-specific synovitis detected by MRI in knee osteoarthritis. Rheumatology (Oxford). 2005;44(12):1569\u201373.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4884_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jbspin.2014.11.002","volume":"82","author":"F Cozzi","year":"2015","unstructured":"Cozzi F, Raffeiner B, Beltrame V, Ciprian L, Coran A, Botsios C, et al. Effects of mud-bath therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical evaluation and assessment of synovial inflammation by contrast-enhanced ultrasound (CEUS). Joint Bone Spine. 2015;82(2):104\u20138.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"4884_CR47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0394632015593220","volume":"29","author":"F Carubbi","year":"2016","unstructured":"Carubbi F, Zugaro L, Cipriani P, Conchiglia A, Gregori L, Danniballe C, et al. Safety and efficacy of intra-articular anti-tumor necrosis factor \u03b1 agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol. 2016;29(2):252\u201366.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"4884_CR48","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/rheumatology\/keab628","volume":"61","author":"MA D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino MA, Schett G, Lopez-Rdz A, Senolt L, Fazekas K, Burgos-Vargas R, et al. Response to secukinumab on synovitis using power doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology (Oxford). 2022;61(5):1867\u201376.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4884_CR49","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/ard.2004.025585","volume":"64","author":"U Fiocco","year":"2005","unstructured":"Fiocco U, Ferro F, Vezzu M, Cozzi L, Checchetto C, Sfriso P, et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis. 2005;64(6):899\u2013905.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4884_CR50","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10067-014-2753-5","volume":"35","author":"I Litinsky","year":"2016","unstructured":"Litinsky I, Balbir-Gurman A, Wollman J, Arad U, Paran D, Caspi D, et al. Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate. Clin Rheumatol. 2016;35(2):363\u201370.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4884_CR51","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","volume":"4","author":"LC Coates","year":"2022","unstructured":"Coates LC, Tillett W, D\u2019Agostino M-A, Rahman P, Behrens F, McDearmon-Blondell EL, et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. The Lancet Rheumatology. 2022;4(4):e262\u201373.","journal-title":"The Lancet Rheumatology"},{"issue":"1","key":"4884_CR52","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","volume":"5","author":"M Koehm","year":"2023","unstructured":"Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-J\u00fcrgens J, Burmester GR, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. The Lancet Rheumatology. 2023;5(1):e14\u201323.","journal-title":"The Lancet Rheumatology"},{"issue":"6","key":"4884_CR53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/ard.2004.024463","volume":"64","author":"AD Fraser","year":"2005","unstructured":"Fraser AD, van Kuijk AWR, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64(6):859\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4884_CR54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s12891-023-06871-3","volume":"24","author":"RS Thomsen","year":"2023","unstructured":"Thomsen RS, Nilsen TIL, Haugeberg G, Sitter B, Kavanaugh A, Pedersen SJ, et al. Changes of inflammation in patients with psoriatic arthritis after high intensity interval training assessed by ultrasound and MRI, a randomized controlled trial. BMC Musculoskelet Disord. 2023;24(1):743.","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"4884_CR55","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00296-006-0102-y","volume":"26","author":"UA Walker","year":"2006","unstructured":"Walker UA, Uhl M, Weiner SM, Warnatz K, Lange-Nolde A, Dertinger H, et al. Analgesic and disease modifying effects of interferential current in psoriatic arthritis. Rheumatol Int. 2006;26(10):904\u20137.","journal-title":"Rheumatol Int"},{"issue":"3","key":"4884_CR56","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.2007.076091","volume":"67","author":"AP Anandarajah","year":"2008","unstructured":"Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67(3):296\u2013301.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4884_CR57","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/ket426","volume":"53","author":"RP Poggenborg","year":"2014","unstructured":"Poggenborg RP, Wiell C, Boyesen P, Boonen A, Bird P, Pedersen SJ, et al. No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology (Oxford). 2014;53(4):746\u201356.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4884_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","volume":"20","author":"E Kampylafka","year":"2018","unstructured":"Kampylafka E, d\u2019Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20(1):153.","journal-title":"Arthritis Res Ther"},{"key":"4884_CR59","doi-asserted-by":"crossref","unstructured":"Fiocco U, Oliviero F, Sfriso P, Calabrese F, Lunardi F, Scagliori E et al. Synovial biomarkers in psoriatic arthritis. J Rheumatol Suppl 2012;89(7806058):61\u201364.","DOI":"10.3899\/jrheum.120246"},{"issue":"1","key":"4884_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s42358-022-00243-6","volume":"62","author":"BF Leite","year":"2022","unstructured":"Leite BF, Morimoto MA, Gomes CMF, Klemz BNC, Genaro PS, Shivappa N, et al. Dietetic intervention in psoriatic arthritis: the DIETA trial. Advances in rheumatology (London, England). 2022;62(1):12.","journal-title":"Advances in rheumatology (London, England)"},{"issue":"Suppl 2","key":"4884_CR61","doi-asserted-by":"publisher","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","volume":"64 Suppl 2","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii61\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4884_CR62","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/art.1780281203","volume":"28","author":"JT Sharp","year":"1985","unstructured":"Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985;28(12):1326\u201335.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4884_CR63","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/028418517701800415","volume":"18","author":"A Larsen","year":"1977","unstructured":"Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh). 1977;18(4):481\u201391.","journal-title":"Acta Radiol Diagn (Stockh)"},{"issue":"8","key":"4884_CR64","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","volume":"140","author":"O Steinbrocker","year":"1949","unstructured":"Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659\u201362.","journal-title":"J Am Med Assoc"},{"issue":"3","key":"4884_CR65","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s003930170064","volume":"60","author":"S Wassenberg","year":"2001","unstructured":"Wassenberg S, Fischer-Kahle V, Herborn G, Rau R. A method to score radiographic change in psoriatic arthritis. Z Rheumatol. 2001;60(3):156\u201366.","journal-title":"Z Rheumatol"},{"issue":"8","key":"4884_CR66","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.090352","volume":"36","author":"M Ostergaard","year":"2009","unstructured":"Ostergaard M, McQueen F, Wiell C, Bird P, B\u00f8yesen P, Ejbjerg B, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. J Rheumatol. 2009;36(8):1816\u201324.","journal-title":"J Rheumatol"},{"issue":"6","key":"4884_CR67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF01375657","volume":"16","author":"D Kalden-Nemeth","year":"1997","unstructured":"Kalden-Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kalden JR. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int. 1997;16(6):249\u201355.","journal-title":"Rheumatol Int"},{"issue":"5","key":"4884_CR68","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.21445","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, et al. Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(5):703\u20139.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4884_CR69","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.rdc.2016.07.006","volume":"42","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Braun J. Imaging scoring methods in axial spondyloarthritis. Rheum Dis Clin North Am. 2016;42(4):663\u201378.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"4884_CR70","first-page":"848","volume":"34","author":"RJ Wakefield","year":"2007","unstructured":"Wakefield RJ, D\u2019Agostino MA, Iagnocco A, Filippucci E, Backhaus M, Scheel AK, et al. The OMERACT Ultrasound Group: status of current activities and research directions. J Rheumatol. 2007;34(4):848\u201351.","journal-title":"J Rheumatol"},{"issue":"5","key":"4884_CR71","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s13075-014-0476-2","volume":"16","author":"A Ficjan","year":"2014","unstructured":"Ficjan A, Husic R, Gretler J, Lackner A, Graninger WB, Gutierrez M, et al. Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). Arthritis Res Ther. 2014;16(5):476.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4884_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12016-012-8304-4","volume":"44","author":"A Anandarajah","year":"2013","unstructured":"Anandarajah A. Imaging in psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):157\u201365.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"4884_CR73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.semarthrit.2021.01.008","volume":"51","author":"A Antony","year":"2021","unstructured":"Antony A, Holland R, D\u2019Agostino M-A, Maksymowych WP, Bertheussen H, Schick L, et al. Measurement properties of radiographic outcome measures in psoriatic arthritis: a systematic review from the GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2021;51(2):367\u201386.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"4884_CR74","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/acr.22104","volume":"66","author":"W Tillett","year":"2014","unstructured":"Tillett W, Jadon D, Shaddick G, Robinson G, Sengupta R, Korendowych E, et al. Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis. Arthritis Care Res. 2014;66(2):311\u20137.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"4884_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101690","volume":"35","author":"AJ Mathew","year":"2021","unstructured":"Mathew AJ, \u00d8stergaard M, Eder L. Imaging in psoriatic arthritis: status and recent advances. Best Pract Res Clin Rheumatol. 2021;35(2): 101690.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"4884_CR76","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3899\/jrheum.181093","volume":"46","author":"AJ Mathew","year":"2019","unstructured":"Mathew AJ, Krabbe S, Eshed I, Gandjbakhch F, Bird P, Pedersen SJ, et al. The OMERACT MRI in enthesitis initiative: definitions of key pathologies, suggested MRI sequences, and a novel heel enthesitis scoring system. J Rheumatol. 2019;46(9):1232.","journal-title":"J Rheumatol"},{"issue":"9","key":"4884_CR77","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3899\/jrheum.181084","volume":"46","author":"S Krabbe","year":"2019","unstructured":"Krabbe S, Eshed I, Gandjbakhch F, Pedersen SJ, Bird P, Mathew AJ, et al. Development and validation of an OMERACT MRI whole-body score for inflammation in peripheral joints and entheses in inflammatory arthritis (MRI-WIPE). J Rheumatol. 2019;46(9):1215.","journal-title":"J Rheumatol"},{"key":"4884_CR78","doi-asserted-by":"publisher","unstructured":"Renkli N, Kleinrensink NJ, Spierings J, Mastbergen S, Vonkeman HE, Mooij SC et al. Multimodal imaging of structural damage and inflammation in psoriatic arthritis: a comparison of DMARD-naive and DMARD-failure patients. Rheumatology (Oxford). 2024\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keae450","DOI":"10.1093\/rheumatology\/keae450"},{"key":"4884_CR79","doi-asserted-by":"publisher","first-page":"E118","DOI":"10.1016\/S2665-9913(24)00232-7","volume":"7","author":"M \u00d8stergaard","year":"2024","unstructured":"\u00d8stergaard M, Boesen M, Maksymowych WP, Lambert RG, Bubb MR, Kubassova O, et al. Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study. Lancet Rheumatol. 2024;7:E118\u201326.","journal-title":"Lancet Rheumatol"},{"key":"4884_CR80","doi-asserted-by":"crossref","unstructured":"Pascu LS, S\u00e2rbu N, Br\u0103deanu AV, Jicman Stan D, Matei MN, S\u00e2rbu MI, et al. MRI findings in axial psoriatic spondylarthritis. Diagnostics (Basel). 2023;13(7).","DOI":"10.3390\/diagnostics13071342"},{"issue":"2","key":"4884_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001057","volume":"5","author":"S Krabbe","year":"2019","unstructured":"Krabbe S, \u00d8stergaard M, Pedersen SJ, Weber U, Kr\u00f6ber G, Makysmowych W, et al. Canada-Denmark MRI scoring system of the spine in patients with axial spondyloarthritis: updated definitions, scoring rules and inter-reader reliability in a multiple reader setting. RMD Open. 2019;5(2): e001057.","journal-title":"RMD Open"},{"issue":"5","key":"4884_CR82","first-page":"3","volume":"36 Suppl 114","author":"S Hassan","year":"2018","unstructured":"Hassan S. Overview of musculoskeletal ultrasound for the clinical rheumatologist. Clin Exp Rheumatol. 2018;36 Suppl 114(5):3\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"4884_CR83","doi-asserted-by":"publisher","first-page":"1759720x2412880","DOI":"10.1177\/1759720X241288060","volume":"16","author":"Y Jin","year":"2024","unstructured":"Jin Y, Cheng IT, Wu D, Yan X, Lau SL, Wong NS, et al. Imaging in psoriatic arthritis: established methods and emerging techniques. Ther Adv Musculoskelet Dis. 2024;16:1759720x241288060.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"1","key":"4884_CR84","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13244-021-01035-0","volume":"12","author":"AM Crespo-Rodr\u00edguez","year":"2021","unstructured":"Crespo-Rodr\u00edguez AM, Sanz Sanz J, Freites D, Rosales Z, Abasolo L, Arrazola J. Role of diagnostic imaging in psoriatic arthritis: how, when, and why. Insights Imaging. 2021;12(1):121.","journal-title":"Insights Imaging"},{"issue":"3","key":"4884_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105651","volume":"91","author":"LC Adams","year":"2024","unstructured":"Adams LC, Bressem KK, Ziegeler K, Vahldiek JL, Poddubnyy D. Artificial intelligence to analyze magnetic resonance imaging in rheumatology. Joint Bone Spine. 2024;91(3): 105651.","journal-title":"Joint Bone Spine"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-025-04884-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-025-04884-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-025-04884-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:04:08Z","timestamp":1758708248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-025-04884-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4884"],"URL":"https:\/\/doi.org\/10.1007\/s00256-025-04884-8","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}